← All indications
Familial Primary Pulmonary Hypertension
Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.
Drugs by status
Approved for this indication (7)
Phase 4 trials (1)
Phase 3 trials (4)
Phase 1 trials (3)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (30)
- United Therapeutics
- Eli Lilly
- Vifor Inc.
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Heart, Lung, and Blood Institute (NHLBI)
- Baylor University
- Cornell University
- Harvard University
- Gottfried Wilhelm Leibniz Universität Hannover
- Johns Hopkins University
- Ochsner Health System
- Postgraduate Institute of Medical Education and Research
- Rhode Island Hospital
- University of Ottawa
- University of Rochester
- University of South Carolina
- Fudan University
- University of California, Los Angeles
- University of California, San Francisco
- University of Chile
- Medical University of South Carolina
- University of Amsterdam
- Free University of Amsterdam
- University of Duisburg-Essen
- INTEGRIS Baptist Medical Center
- Technical University of Dresden
- CVie Therapeutics Co. Ltd.
- Asian Clinical Trials
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (38)
- Acceleron Pharma, Inc.
- Encysive
- Novartis
- Arena Pharmaceuticals
- Dong-A Pharmaceutical
- GlaxoSmithKline
- Liquidia Technologies, Inc.
- Lung Biotechnology PBC
- Mallinckrodt
- Reata Pharmaceuticals, Inc.
- Vero Biotech
- University of Arizona
- University of London
- Northwestern University
- Seoul National University
- Tufts University
- Yonsei University
- Chonbuk National University
- Competence Network for Congenital Heart Defects
- University of Ulsan
- Covance
- Chungnam National University
- Worldwide Clinical Trials
- Bellerophon Therapeutics
- Catholic University of Korea
- Chiltern International
- University of Paris
- Technical University of Munich
- German Federal Ministry of Education and Research
- Chonnam National University
- +8 more
Organization Involved with Phase 2 Indications (45)
- PPD
- Roche
- Aires Pharmaceuticals, Inc.
- CoTherix
- Eiger BioPharmaceuticals
- FGK Clinical Research GmbH
- PhaseBio Pharmaceuticals Inc.
- Boehringer Ingelheim
- Complexa, Inc.
- ZonMw: The Netherlands Organisation for Health Research and Development
- Medical Research Council
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pennsylvania
- University of Pittsburgh
- Medical University of Graz
- Georgetown University
- Los Angeles Biomedical Research Institute
- Stanford University
- Sheffield Hallam University
- Justus Liebig University Giessen
- University of Maryland
- University of Toronto
- Virginia Commonwealth University
- Columbia University
- Peking University
- University of Cambridge
- Vanderbilt University
- Papworth Hospital NHS Foundation Trust
- University of Minnesota
- Jiao Tong University
- +15 more
Organization Involved with Phase 1 Indications (17)
- Biomarin
- Merck
- Parexel
- Shahid Beheshti University of Medical Sciences
- Huazhong University of Science and Technology
- Central South University
- Cedars-Sinai Medical Center
- Masih Daneshvari Hospital
- Ohio State University
- Chongqing Medical University
- Laval University
- University of Chicago
- University of Queensland
- California Institute for Regenerative Medicine
- Shantou University
- Gossamer Bio Inc.
- Gmax Biopharm Australia Pty Ltd.
Organization Involved with Other Experimental Indications (8)